ArticleAddiction science & clinical practice2026
Experiences of non-prescribed opioid use during opioid agonist therapy: an interpretative phenomenological analysis.
Article in Addiction science & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the goal of opioid agonist therapy is typically understood by clinicians to be the cessation of the use of non-prescribed opioids, many people taking opioid agonist therapy continue to use other opioids. The purpose of this study was to explore how people who use both prescribed opioid agonist therapy and non-prescribed opioids understand their use of both agents.
methodsAn interpretative phenomenological analysis was conducted with ten participants recruited from harm reduction sites in Toronto who were concurrently using opioid agonist therapy and non-prescribed opioids. Semi-structured interviews were audio-recorded and transcribed verbatim. Data were analysed to explore participants' understanding of their use of both opioid agonist therapy and non-prescribed opioids.
resultsParticipants had unique reasons for the use of opioid agonist therapy and non-prescribed opioids; while opioid agonist therapy is free, relatively safe, and helps control opioid withdrawal symptoms, non-prescribed opioids satisfy opioid cravings, ease physical and emotional pain, and can be used with more autonomy. The participants' relationships with different opioids are complicated, and some struggle to reconcile their use with their goals.
conclusionsParticipants shared that opioid agonist therapy and non-prescribed opioids fill complementary roles in their lives, each presenting their own benefits and challenges. Their experiences highlight opportunities for improving the provision of opioid agonist therapy in order to make it more effective and acceptable for people who use non-prescribed opioids, which is a crucial strategy in combatting mortality from the opioid toxicity crisis. Opioid agonist therapy can thus be situated within the harm reduction continuum as a practice that can be beneficial whether or not it results in abstinence, and clinicians should offer tailored regimens that take patient preferences and goals into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.